Cannabis for Sickle Cell Pain: Promising but Evidence Is Thin | Research

The takeaway

A scoping review of 12 studies found mixed but generally positive evidence for cannabis in managing sickle cell disease pain, with inhaled cannabis showing the most promise for acute pain, though safety concerns remain about synthetic cannabinoids.

Hematologists treating sickle cell disease, SCD patients using cannabis for pain, pain management specialists, and researchers prioritizing cannabinoid studies.

What the researchers found

Of 12 qualifying studies (1 clinical trial, 2 reviews, 7 observational, 1 mixed-methods, 1 qualitative), evidence was mixed but generally positive for cannabinoid effectiveness in SCD pain — with some studies showing reduced pain scores from inhaled cannabis, though results varied for hospitalizations and raised safety concerns for synthetic cannabinoids.

Why it matters

Sickle cell disease causes severe chronic pain with limited treatment options, and patients increasingly use cannabis — yet the evidence base is remarkably thin, consisting of just one clinical trial and mostly observational data.

The numbers in context

369 articles screened; 12 included (1 clinical trial, 2 reviews, 7 observational, 1 mixed-methods, 1 qualitative); inhaled cannabis showed pain reduction; mixed results for vaso-occlusive crisis hospitalizations; no exacerbation of SCD symptoms

How the study worked

Scoping review following PRISMA-ScR guidelines, searching PubMed, CINAHL, and Cannakeys for studies on cannabis use in adult SCD patients addressing pain, yielding 12 of 369 screened articles.

What this study cannot tell us

Only 12 qualifying studies with just 1 clinical trial; heterogeneous study designs; variable cannabis types and routes; observational studies subject to confounding; scoping review format doesn't assess quality; limited generalizability.

How to read the evidence

Scoping review reveals a critically thin evidence base dominated by observational studies, making definitive conclusions impossible despite generally positive signals.

When this study was published

Published 2026; comprehensive search through current literature.

The bigger picture

SCD disproportionately affects Black communities who already face barriers to pain treatment — cannabis could fill an important therapeutic gap if properly studied, but the research has not kept pace with patient use.

Questions still open

Should clinical trials of cannabis for SCD pain be prioritized given patient demand? Could cannabis reduce opioid dependence in SCD patients? What cannabis formulations and routes are optimal for different types of SCD pain?

Common questions

Can cannabis help with sickle cell pain?

The limited evidence is generally positive — inhaled cannabis has shown pain reduction in some studies, and no studies found cannabis worsened SCD symptoms. But with only one clinical trial among 12 total studies, the evidence is far too thin for firm conclusions.

Is cannabis safe for sickle cell disease patients?

Natural cannabis products showed no exacerbation of SCD symptoms, but safety concerns were raised about synthetic cannabinoids. More research is urgently needed given how many SCD patients already use cannabis for pain management.

Read the original research

Cannabis Use for Chronic Pain in Sickle Cell Disease: A Scoping Review.

Pain management nursing : official journal of the American Society of Pain Management Nurses, 27(1), e17-e25

View on PubMed ↗Publisher’s paper ↗

Citation

Jackson, Simone B; Payton, Isaac; Powell-Roach, Keesha; Starkweather, Angela; Cook, Robert L; Varma, Deepthi S; Terry, Ellen L; Booker, Staja Q. (2026). Cannabis Use for Chronic Pain in Sickle Cell Disease: A Scoping Review.. Pain management nursing : official journal of the American Society of Pain Management Nurses, 27(1), e17-e25. https://doi.org/10.1016/j.pmn.2025.06.010